HM7: Paediatric investigational plans

By David Uguen2023-12-05T16:00:00

In her introduction, Sandra Lourenco explained that even though the EU’s paediatric legislation came into effect more than 15 years ago, much medical need persists in the paediatric population. Global development of paediatric medicines can be facilitated by strengthening the international collaboration and alignment of regulatory requirements for PIPs. Therefore, it is important to collectively continue our efforts to develop medicinal products suitable for use in paediatric patients.

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

1. REGISTER FOR FREE

Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

Create your own library to save your favourite content.

Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

3. JOIN TOPRA

Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member